Press Releases

Date Title and Summary View
Toggle Summary Oxford Immunotec Reports Second Quarter 2017 Financial Results
Second quarter revenue of $26.1 million, an increase of 36% compared to prior year period Continued growth from both the Tuberculosis and Tick-borne disease franchises Successful negotiation of a settlement with Statens Serum Institut which will result in substantial future gross margin improvement
View HTML
Toggle Summary Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Schedules Second Quarter 2017 Earnings Release and Conference Call for August 1, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions,
View HTML
Toggle Summary Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Names Karen Koski Head of Strategy and Investor Relations
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Reports First Quarter 2017 Financial Results
First quarter revenue of $21.5 million, an increase of 26% compared to prior year period First quarter Tuberculosis revenue of $18.5 million, an increase of 8% compared to prior year period First quarter Tick-borne disease and other revenue of $3.0 million OXFORD, United Kingdom and MARLBOROUGH,
View HTML
Toggle Summary Oxford Immunotec Schedules First Quarter 2017 Earnings Release and Conference Call for May 2, 2017
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 19, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated
View HTML
Toggle Summary Oxford Immunotec Announces Release of New National Tuberculosis Test Data and Screening Grant for High Risk Patients on World TB Day
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today
View HTML
Toggle Summary Oxford Immunotec Reports Fourth Quarter and Full Year 2016 Financial Results
Fourth quarter revenue of $23.7 million, an increase of 41% compared to prior year period Fourth quarter Tuberculosis revenue of $20.4 million, an increase of 22% compared to prior year period Fourth quarter Tick-borne disease and other revenue of $3.3 million Full year 2016 revenue of $86.1
View HTML